Sara M. Tolaney

Sara M. Tolaney

Oncology
450 Brookline Avenue
Susan F. Smith Center For Women's Cancers
Boston, MA 02115

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 457 publications

Minimal Residual Disease via circulating tumor DNA Predicts Exceptional Response in HER2-Positive Metastatic Breast Cancer.

Minimal Residual Disease via circulating tumor DNA Predicts Exceptional Response in HER2-Positive Metastatic Breast Cancer.

Journal: medRxiv : the preprint server for health sciences
Published: July 30, 2026

Economic value of ribociclib in early breast cancer in the United States.

Economic value of ribociclib in early breast cancer in the United States.

Journal: Journal of managed care & specialty pharmacy
Published: July 27, 2026

Clinical toxicity of ADCs and ICI-ADC combinations: mechanisms, patterns and management.

Clinical toxicity of ADCs and ICI-ADC combinations: mechanisms, patterns and management.

Journal: Nature reviews. Clinical oncology
Published: July 14, 2026

Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe Trial.

Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe Trial.

Journal: JAMA oncology
Published: June 25, 2026

Longitudinal multi-platform profiling reveals temporal dynamics of HER2, TROP2, PD-L1 and tumor-infiltrating lymphocytes in triple-negative breast cancer.

Longitudinal multi-platform profiling reveals temporal dynamics of HER2, TROP2, PD-L1 and tumor-infiltrating lymphocytes in triple-negative breast cancer.

Journal: medRxiv : the preprint server for health sciences
Published: June 05, 2026

Circulating Tumor DNA in Early Breast Cancer: A Review.

Circulating Tumor DNA in Early Breast Cancer: A Review.

Journal: JAMA oncology
Published: May 28, 2026

Elacestrant in Combination with Everolimus for Estrogen Receptor-Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE.

Elacestrant in Combination with Everolimus for Estrogen Receptor-Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 17, 2026

Stage IV Breast Cancer Incidence and Survival, 2010-2021.

Stage IV Breast Cancer Incidence and Survival, 2010-2021.

Journal: JAMA network open
Published: May 12, 2026

HER2DX in early-stage HER2-positive breast cancer: a review of clinical utility.

HER2DX in early-stage HER2-positive breast cancer: a review of clinical utility.

Journal: ESMO open
Published: April 11, 2026

TRADE: tolerability of adjuvant abemaciclib at 6 months after initial dose escalation in patients with early-stage HR-positive/HER2-negative breast cancer.

TRADE: tolerability of adjuvant abemaciclib at 6 months after initial dose escalation in patients with early-stage HR-positive/HER2-negative breast cancer.

Journal: ESMO open
Published: April 10, 2026

Survival and Treatment Patterns in Stage III Inflammatory and Noninflammatory Breast Cancer.

Survival and Treatment Patterns in Stage III Inflammatory and Noninflammatory Breast Cancer.

Journal: JAMA network open
Published: April 09, 2026

New perspectives on endocrine therapy suitability for hormone receptor-positive metastatic breast cancer in clinical practice.

New perspectives on endocrine therapy suitability for hormone receptor-positive metastatic breast cancer in clinical practice.

Journal: Breast (Edinburgh, Scotland)
Published: April 08, 2026
Showing 1-12 of 457

Last Updated: 09/26/2026